Alex T.

Alex T. has worked in a variety of roles in the biopharmaceutical industry since 2001. Alex began their career as a Research Scientist at Bayer HealthCare in 2001. In 2004, they moved to KBI Biopharma, Inc. as a Director. In 2009, they joined Novartis Vaccines and Diagnostics as Global Head of Manufacturing Science and Technology, responsible for a total staff of approximately 130 engineers and scientists at four commercial manufacturing sites in the US and Europe. In 2012, they became Head of Manufacturing Science & Technology (Sterile Injectables) and Lead Director of Manufacturing Science & Technology at Hospira. In 2016, they took on the role of VP, Pharmaceutical Development & CMC at Roivant Sciences, Inc./Enzyvant. In 2020, they became Chief Technical Officer at Istari Oncology. In 2021, they took on the same role at BridgeBio Gene Therapy. Alex currently serves as Chief Technical Officer at Code Biotherapeutics.

Alex T. obtained a PhD in Biochemistry & Molecular Biology from The University of Georgia in 2001, and an MS in Chemistry from George Mason University.